Canadian Securities ExchangeThe Daily Bell

Novamind Inc. (CSE:NM) w/ Yaron Conforti

New Canadian Stocks

February 8, 2021Newly Listed on the CSE

(CSE:NM)

About This Video

Novamind Inc. is a newly listed public company on the Canadian Securities Exchange stock market under the symbol NM.

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca.

For more information head to: https://thecse.com/en/listings/novamind-inc

Subscribe for more great CSE insights and interviews here: https://bit.ly/CSETVSubscribe

STAY CONNECTED WITH THE CSE

=============================

- PODCAST: https://blog.thecse.com/pe-podcasts/

- INSTAGRAM: https://www.instagram.com/canadianexchange/

- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange

- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/

- TWITTER: https://twitter.com/CSE_News

- BLOG: https://blog.thecse.com/

- WEBSITE: https://thecse.com/

Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.

hi welcome to newly listed with the canadian securities exchange i'm your host barrington miller director of issuer engagement and today i'm here with jaren conforti ceo director and co-founder of novamind inc welcome to the show hey barrington good to be here tell us about what nova mine does sure novamind is focused on psychedelic medicine specifically we're building infrastructure for the psychedelic medicine sector so we operate a network

of mental health clinics there's four of them in operation and we also operate a cro which stands for contract research organization and that platform serves pharmaceutical clients academic institutions and other not-for-profits that are looking for drug development services as you know this industry has sort of sort of taken off and for novamind you have recently listed and gone public on the canadian securities exchange i know that you made a few key hires and

you expanded your clinic capacity that was that was in january tell us a little bit more about that you know in short we partnered our way into this business so you're absolutely right there's a huge amount of interest obviously and capital flowing to the the psychedelic medicine sector when when we started the thesis was really we incorporated the company about two years ago so i'm a co-founder of this company and

i have two co-founders that are still on the board two years ago we incorporated the company and and started making investments with a thesis that we were really seeking out the people that were treating people today so where we ended up cutting a long story short is we in fact made some investments abroad in the netherlands where psilocybin is legal but more importantly we made two

acquisitions in the united states and those are our two core platforms so the first is cedar psychiatry and that's the the four mental health clinics that i mentioned and that's a network that's expanding very quickly and the cro i also described so we acquired both of those entities and they're now 100 owned by us and really the platform we're building is based on the pillars that existed in those

businesses so those businesses were founded by dr reed robison he's now our chief medical officer dr robison is also a coordinating investigator for the maps phase three clinical trial using mdma he is both a clinician and a researcher so essentially we were able to partner with someone who was already very far along for many years now and well known in advancing psychological medicine not only in terms of

research to bring new drugs to market but in terms of providing the legal options that are available today to his patients so making those acquisitions really allowed us to leapfrog instead of waiting for the advent of psychedelic medicine we're in the business of using the existing alternative health modalities which i'll talk about there are treatments that people can get now and legally and safely that are alternatives to the standard of care

you know most of which people are familiar with involve some combination of ssris or antidepressants and some form of cognitive behavioral therapy right so these are are the things the these the modalities if you will or mental health approaches that we're familiar with in many cases they don't work our businesses are focusing on not only offering the existing modalities but the alternative ones it's it's interesting that we're

talking a lot more about mental health for our audience and our listeners if you are outside of canada we have something called bell let's talk that discuss mental health and the beginning of the process that was last month we've seen a there's been a huge growth in this industry i believe there's been a 100 growth in clinic visits between 2019 and 2020. how is novamind meeting that demand

by growing in short so so again yeah you mentioned the 100 percent growth over a year what we've done is we've published some news and we've looked at the operating statistics from calendar 2020. so we looked at the segments that are growing the amount of client visits we saw in 2019 the total was around 10 000 and the amount we saw in 2020 was over 20 000.

so the demand certainly is there it's exacerbated from our perspective in terms of again the incoming that we have and we're not a heavily marketed business business i'll also add so much of it is new patient and referral business people seeking out those alternatives so the answer to your question barrington is to to create access points and that's really what how i think of our alternative mental health clinics and if

you know the largest group of people if you consider are people that don't know about the alternative treatments they don't have connections to people like me or maybe psychiatrists or people that can lead them down this path so we want to make it effectively an on-ramp if you will for people that are looking for that alternative care and and aren't well served by the standard of care to provide as i said an access point

where when they come into one of our clinics just to give you a picture of what what you'd see it's that spectrum of services i described so cbt cognitive behavioral therapy or a psychiatrist that can prescribe a new prescription management maybe a nutritionist on staff approaching more holistic care these are some of the more traditional or or typical services and when you add things like our specializations in ketamine-assisted

psychotherapy which people could access legally ketamine being effectively the first legal psychedelic we offer spervato which is the first prescription form of ketamine we offer tms which is an acronym for transcranial magnetic stimulation so these are regulated and approved mental health alternatives that are not widely available where people would maybe have to go to a special place for specialized care we want to create the opportunity where

anybody can access that spectrum of alternative mental health modalities as easy as possible so that's how we that's how we expand access and feed that demand that we're seeing we've we've run a few different i guess psilocybin psychedelic investing in psychedelic conferences and one of the things the renaissance of psychedelics and that's one of the themes that came up a lot was access and access to and working

alongside some organizations like maps they're they're truly truly heavyweights a lot of young companies that are in the space in psychedelics how is nova mind positioned really strongly when it comes to the science and mental health and evidence based why why is it so important for nova mine to be in that place i think it's ultra important and i think it's it has to do with

the particular part of the value chain that we're filling in psychedelics so you've mentioned lots of companies lots of entrepreneurs lots of capital funds this sector you'll find the majority of that money and the majority of those business models are focused on drug development you know also known as biotech investments and it's it's a very well understood model and it's a very lucrative model and that is essentially you're spending hundreds of

millions over a 10-plus year period towards drug approval so that you can get patent protection and sell those drugs that is not our business model and that is why it's important that we succeed and i think we're very very well positioned to succeed success for us means scaling our clinics and scaling our clinical research sites and the two you really go hand in hand and there's a symbiotic relationship there so

when you ask you know why it's important that nova mine holds this position and we could argue it's important for many companies but i'll focus in terms of advancing psychedelic medicine and bringing alternatives to people that need them i think nova mine plays a unique role and that is first of all we've described our our mental health clinics and and it's it's essentially taking a some of the parts sort of approach

that if you put all those alternative health modalities under one roof and if you put the people who are experienced in practice they're training and helping people with them then you're by definition you're you're aggregating you know some very very specialized expertise and putting it all in one place for the people that need them the goal there to be really clear is that not all modalities or therapies are for all

people so unless you have that spectrum and you take that personalized medicine approach you try and match the treatment to the patient you really can't fulfill that as a goal unless you have the the breadth of services and again the training to offer those services because these are not self-administered treatments the second part of it is the the clinical research part so i mentioned our cmo dr robison is one

of the coordinating investors in the maps phase 3 trial we're also involved in studies with the ketamine research foundation around end of life distress and you know there's some other studies including tourette's syndrome and borderline personality disorders some involving some of the largest pharmaceutical companies in the world so our offering when people understand the role that we're playing in bringing the drugs to market which again i'll point out that most of

these drugs are not self-administered in psychedelic medicine it means you you have to have you have to adhere to a therapeutic protocol to do this properly you have to have trained therapists apply those protocols so our you know certainly our model our expectation is if we are trusted to bring these drugs to market through the clinical trial process much like we're involved in the mdma trials then we expect to be trusted as a safe

resource for people to access these experiences from themselves and i don't know to date anybody that has quite our model where again we're both advancing psychedelic medicine in the clinic and providing it as clinicians to our clients so that that combination becomes really really powerful you mentioned a couple points your your research arm and your clinic network and i know you're running a lot of

clinical trials on psychedelic medicine for major pharmaceutical companies like you mentioned i'm gonna name drop like johnson johnson jansen it's the location of where you're doing it and for our audience and listeners it's in utah why utah that's a fair question right of all the states why that state the short answer is dr reed ross that's where dr reed robinson is based that's where he built

the initial sites for our network of clinics and that's where our dedicated research site is for cedar clinical research so you know i it was interesting when we made the acquisition and pre-covered i was spending quite a bit of time going back and forth to utah what i realized pretty quickly that many people may not about utah is that it's a pretty exciting story and so far is that you have a very large

affluent and educated workforce you have companies like goldman sachs google amazon and other that have set up you know the major basis there like i think goldman is the largest outside of the outside of new york and they're doing that because it's it's it's grown very very quickly it's been referred to as a silicon slopes if you look that up you'll you'll see a lot of media around that because the

tech company is being attracted there so yeah we're we're in utah for for very particular reasons and that's because our cmo is there and because it's in fact a growth market where people have embraced you know our our clinic model it's where it's got its start we owe it to them so that's over there but it's just the starting point you'll see news from us growing

out of that state we'd like to be in we're prioritizing other states in the united states obviously and as well canada has had a lot of policy moves that we're excited about and providing access for example to end of life distressed patients under a special exemption that's for us symbolic right that the policy is starting to shift and we want to be in place operating in places where the

policy is going to shift because those are the jurisdictions they're going to bring alternative therapies to market the quickest and this segues into my final question when you talked about at least things coming out of utah in the future of what are the milestones that viewers soon to be investors would be investors current investors have to look forward to in the next coming months you know broad

broadly growth are the milestones specifically that comes in the form of we're opening clinics so for organic and mna there's a pipeline for both for us to expand our clinics and investors will be seeing that in the coming weeks and months and again the the corollary to that is the clinical trite clinical site expansion excuse me so the clinical site expansion allows us to offer those pharmaceutical companies and

drug developers a more let's say comprehensive offering you're a much better position when you can offer multi-site in a single site and so you can expect to see expansion of sites expansion expanding the sites and then expanding the research trials that go with those sites and on the clinic side again expanding into new jurisdictions and bringing that model to serve patients wherever we can yarn i want to thank you not only for

your time but also for your listing i want to thank you and your team on behalf of the canadian securities exchange for choosing to be here with us and for telling us about your company novamind proudly training on the canadian securities exchange i've been your host barrington miller here with jaron conforti ceo director and co-founder of novamind this has been a newly listed clip thank you thank you thank you for tuning

in to another newly listed on the csc please feel free to hit like and share this content and hit subscribe if you haven't already

More Newly Listed on the CSE

See them all

Tiger Financial (CSE:BANQ)From Cash to DigitalOct 27, 2026
Caldwell-Lazard CorePlus Infrastructure Fund (CSE:CPIF)Sep 14, 2026
SECUR3D Holdings (CSE:SRD)AI-Powered Brand ProtectionSep 8, 2026
Secur3D Holdings (CSE:SRD)AI-Powered Brand & IP ProtectionAug 20, 2026